To further investigate the differentiation phenotype after CAR-T cells encountered CD19 + PDL1 + tumor cells, we validated the reported gene signature associated with CAR-T cell efficacy through transcriptomic profiling [32]. The gene discussed is CD19; the disease is neoplasm.